Effects of whole body vibration and core exercise on muscle soreness and performance during a foot march

Effects of a whole body vibration and core exercise intervention on muscle soreness and performance during a foot march: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12264516

Enrollment

Registered

2020-10-16

Start date

2019-07-15

Completion date

Unknown

Last updated

2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low back pain Musculoskeletal Diseases Low back pain

Interventions

Study volunteers will be randomly allocated by the researchers, using a random number generator, into one of three groups: 1. Whole body vibration with core exercise 2. Core exercise only 3. Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 19-35 years

Exclusion criteria

Exclusion criteria: 1. Acute inflammation and infections 2. Acute joint disorders or arthroses 3. Chronic migraine headaches 4. Cardiovascular diseases, such as heart and vascular 5. Recent joint implants such as foot, knee, and implants 6. Heart rhythms or valve disorders 7. Recently placed metal or synthetic implants such as pacemakers and cochlear implants 8. Pregnancy, gallstones, or epilepsy 9. Recent thrombosis or possible thrombotic complaints 10. Tumors, diabetes, or kidney stones 12. Have a current concussion or a concussion within the last 90 days 13. Allergic to adhesives

Design outcomes

Primary

Measure	Time frame
1. Low back pain measured using a visual analog scale before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks 2. Low back soreness measured using an algometer before, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks	—

Secondary

Measure	Time frame
1. Performance measured as time to complete the 8 km distance measured at the completion of the foot march at 0 and 3 weeks 2. Muscle Damage measured from blood draws taken before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks 3. Muscle Activation measured with surface electromyography (EMG) sensors during the foot march at 0 and 3 weeks 4. Exertion Level measured with Borg rating of perceived exertion scal before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks 5. Muscle Oxygenation measured with Humon Hex device (worn on the upper thigh), before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks 6. Posture measured with a Zephyr Bioharness (worn around the chest), before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks	—

Measure

Time frame

1. Performance measured as time to complete the 8 km distance measured at the completion of the foot march at 0 and 3 weeks 2. Muscle Damage measured from blood draws taken before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks 3. Muscle Activation measured with surface electromyography (EMG) sensors during the foot march at 0 and 3 weeks 4. Exertion Level measured with Borg rating of perceived exertion scal before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks 5. Muscle Oxygenation measured with Humon Hex device (worn on the upper thigh), before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks 6. Posture measured with a Zephyr Bioharness (worn around the chest), before, half-way through, immediately after, and 1 day and 2 days following each foot march at 0 and 3 weeks

—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026